Clinical Trial

Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias

Name: Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias — clinical trial record (NCT07765966)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: POPULUS-1

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The Phase 1 is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RXIM002 in patients with relapsed or refractory autoimmune cytopenias.

Trial Details

NCT Number	NCT07765966
Lead Sponsor	RiboX Therapeutics Ltd.
Conditions	Relapsed or Refractory Autoimmune Cytopenias, Immune Thrombocytopenia (ITP)
Enrollment	27 participants
Start Date	2027-02-01
Primary Completion	2028-06-30 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-14